Published in Medical Patent Week, December 5th, 2004
The product will be marketed by IVAX' U.S. proprietary products subsidiary, IVAX Laboratories, Inc. IVAX has previously received an approvable letter from the FDA on its NDA for albuterol HFA (CFC-free) in the company's patented, breath-activated inhaler, known in Europe as Easi-Breathe.
Neil Flanzraich, vice chairman and president of IVAX Corporation, said, "Products for treating respiratory disease have become...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.